市場調査レポート
商品コード
1496719
抗体治療薬市場:フォーマット、投与経路、供給源、疾患領域、エンドユーザー別-2024-2030年の世界予測Antibody Therapeutics Market by Format (Antibody Fragment, Bispecific Antibody, Monoclonal Antibody), Route of Administration (Intravenous, Subcutaneous), Source, Disease Areas, End User - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
抗体治療薬市場:フォーマット、投与経路、供給源、疾患領域、エンドユーザー別-2024-2030年の世界予測 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
|
抗体治療薬市場規模は、2023年に2,487億9,000万米ドルと推定され、2024年には2,857億7,000万米ドルに達し、CAGR 14.89%で2030年には6,575億米ドルに達すると予測されています。
抗体治療薬は、免疫系が病気と闘う能力を模倣または強化するために抗体を使用する一群の治療法です。抗体治療薬の精度の高さは、従来の薬剤よりも高い特異性と低い毒性プロファイルを提供するオーダーメイド治療を可能にし、がん、自己免疫疾患、感染症を含む様々な症状の治療に効果的です。慢性疾患の増加と世界のヘルスケア支出の増加により、抗体治療薬の採用が増加しています。しかし、開発に伴う高額なコストや長く複雑な規制当局の承認が、抗体治療薬の普及を制限しています。とはいえ、医療技術の進歩は、より生産性の高い抗体作製につながっています。加えて、次世代抗体の出現や、がん治療・ケアに対する政府の支援イニシアティブは、抗体治療薬市場に潜在的な機会を提供すると期待されています。
主な市場の統計 | |
---|---|
基準年[2023] | 2,487億9,000万米ドル |
予測年[2024] | 2,857億7,000万米ドル |
予測年 [2030] | 6,575億米ドル |
CAGR(%) | 14.89% |
地域別インサイト
南北アメリカでは、確立された研究開発エコシステム、広範な特許ポートフォリオ、高いヘルスケア支出に支えられ、抗体治療薬市場は力強い成長を示しています。さらに、南北アメリカには数多くのバイオ医薬品大手が存在し、モノクローナル抗体や新薬の開発に多大な資源を投入しています。アジア太平洋地域は、ヘルスケア・インフラの成長と慢性疾患の増加により、抗体治療薬に対するニーズが急増しました。さらに、アジア太平洋地域は、強力な研究機関と政府の支援政策に支えられた個別化医療と抗体開発の進歩により、抗体治療薬市場の成長を目の当たりにしています。強力な製薬産業、広範な研究イニシアティブ、包括的な知的財産権の枠組みを持つ欧州連合(EU)諸国は、抗体治療薬の展望において極めて重要です。さらに、中東やアフリカの国々は、最先端の医療施設やヘルスケア・イノベーションに投資しています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは抗体治療薬市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、抗体治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、抗体治療薬市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[197 Pages Report] The Antibody Therapeutics Market size was estimated at USD 248.79 billion in 2023 and expected to reach USD 285.77 billion in 2024, at a CAGR 14.89% to reach USD 657.50 billion by 2030.
Antibody therapeutics are a class of medical treatments that employ antibodies to mimic or enhance the immune system's ability to fight diseases. The precision of antibody therapeutics allows for tailored treatments that provide high specificity and lower toxicity profiles than conventional drugs, making them effective in treating various conditions, including cancers, autoimmune diseases, and infectious diseases. The increasing incidences of chronic diseases and increased healthcare expenditure globally have increased the adoption of antibody therapeutics. However, high costs associated with development and lengthy and complex regulatory approvals limit the penetration of antibody therapeutics. Nevertheless, advancements in medical technology are leading to more productive antibody production. In addition, the emergence of next-generation antibodies and supportive government initiatives for cancer care and treatments are expected to offer potential opportunities for the antibody therapeutics market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 248.79 billion |
Estimated Year [2024] | USD 285.77 billion |
Forecast Year [2030] | USD 657.50 billion |
CAGR (%) | 14.89% |
Regional Insights
In the Americas, antibody therapeutics market exhibit robust growth supported by a well-established R&D ecosystem, extensive patent portfolio, and high healthcare expenditure. Furthermore, the Americas includes numerous biopharmaceutical giants, which dedicate substantial resources to developing monoclonal antibodies and novel drug discovery. The Asia-Pacific region experienced a surge in the need for antibody therapeutics due to a growing healthcare infrastructure and increased incidences of chronic disease. Moreover, the Asia-Pacific region is witnessing growth in the antibody therapeutics market owing to the advances in personalized medicine and antibody development, supported by its strong research institutions and supportive government policies. Given their strong pharmaceutical industry, extensive research initiatives, and comprehensive intellectual property rights framework, European Union countries are pivotal in the antibody therapeutics landscape. In addition, countries in the Middle East and Africa are investing in state-of-the-art medical facilities and healthcare innovation.
Market Insights
The market dynamics represent an ever-changing landscape of the Antibody Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Antibody Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
SystImmune entered into a pivotal license and collaboration agreement with Bristol Myers Squibb that focuses on the co-development and commercialization of the innovative BL-B01D1, an EGFRxHER3 bispecific antibody-drug conjugate (ADC) that is promising as a first-in-class therapy. Currently undergoing a Phase 1 clinical trial targeting non-small cell lung cancer (NSCLC), BL-B01D1 has already exhibited significant anti-tumor activity and a well-managed safety profile across various solid tumors. [Published On: 2023-12-11]
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
AbbVie Inc. partnered with BigHat Biosciences to drive the creation of cutting-edge therapeutic antibodies for oncology and neuroscience. This collaboration aims to streamline the discovery and optimization of superior antibodies for several key therapeutic targets. This initiative reflects the company's dedication to integrating AI and ML advancements into the drug development workflow to expedite the delivery of effective treatments. [Published On: 2023-12-05]
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
AbbVie announced the acquisition of ImmunoGen, a significant development that includes control of rights of ELAHERE (mirvetuximab soravtansine-gynx), ImmunoGen's premier cancer therapy. This acquisition is a testament to AbbVie's commitment to expanding its solid tumor treatment capabilities, positioning it to better address the complexities of cancer care. [Published On: 2023-11-30]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Antibody Therapeutics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc.,, Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc..
Market Segmentation & Coverage